StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Heron Therapeutics's price to sales ratio was 0.4× on Nov 11, 2026, against 1.3× a year earlier. Over the last 5 years it ranged from 0.3× to 18.0×, with a median of 2.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.4×−1.0
2025Dec 31, 20251.4×−0.3
2024Dec 31, 20241.7×−0.1
2023Dec 29, 20231.7×−3.6
2022Apr 29, 20225.3×−4.8
2021Dec 31, 202110.1×−8.4
2020Dec 31, 202018.5×+5.2
2019Dec 31, 201913.3×−16.8
2018Dec 31, 201830.1×−10.6
2017Dec 29, 201740.7×–

More Heron Therapeutics figures

See a number that looks wrong?